Venus Remedies, the Chandigarh-based pharmaceutical company, reported excellent financial performance during the year ended March 2006 and its net profit has taken a quantum jump to Rs 16.85 crore from Rs 4.10 crore in the previous year. Its net sales also increased smartly by 270 per cent to Rs 92.09 crore from Rs 34.09 crore. With smart gain in profitability, its earning per share went up to Rs 20.05 from Rs 6.40 in the last year.

The company's German subsidiary Venus Pharma GmbH acquired a running German GMP certified pharmaceutical unit and entered into regulated European markets. Venus filed its fourth PCT application for grant of international patent of its R&D formulation.

The clinical trials of the new FDC of Cephalosporin with Amlnoglycoside developed by the R&D wing of the company were successfully completed. The clinical Care Product is a sure shot remedy for H.A.P (Hospital acquired Pneumonia) and shall be launched shortly, for the first time globally, in a market worth US$ 1 billion. The company added three major companies i.e. Wockhardt, Alembic and Indoo Remedies to its customer list. Its domestic division launched three new products viz., Injection Mega-pred, Inj. Fejet and Inj. Sou-Cort and received good response. The marketing division added 29 new headquarters under its territory expansion plan in the sates of Madhya Pradesh, Maharashtra and Uttaranchal.